Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | PRKCI | P41743 | 1/20 | 0.31 |
| ▸ | NQO2 | P16083 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18651580 | 0.77 | HSD11B1 (0.37) | HSD11B1KDM4EALDH1A1MAPTRXFP1 | |
| SCHEMBL19499083 | 0.76 | CYP1A2 (0.36) | CCR4KDM4EALDH1A1MAPT | |
| SCHEMBL18876115 | 0.76 | KDM4E (0.36) | HSD11B1KDM4EALDH1A1MAPTRXFP1 | |
| SCHEMBL31277200 | 0.74 | HSD11B1 (0.33) | HSD11B1KDM4EALDH1A1MAPTRXFP1 | |
| SCHEMBL2627063 | 0.72 | CCR4 (0.48) | CCR4HSD11B1KDM4EALDH1A1MAPT | |
| SCHEMBL26200048 | 0.70 | CCR4 (0.32) | CCR4KDM4EALDH1A1MAPT | |
| SCHEMBL14616909 | 0.69 | CCR4 (0.37) | CCR4HSD11B1KDM4EALDH1A1MAPT | |
| SCHEMBL23709554 | 0.67 | RHEB (0.56) | KDM4EMAPTRXFP1 | |
| SCHEMBL16626053 | 0.67 | POLB (0.38) | CCR4HSD11B1KDM4EALDH1A1MAPT | |
| SCHEMBL6050596 | 0.67 | MAT2A (0.44) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250082-A1 | 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS | IP2IPO INNOVATIONS LIMITED (GB) | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250082-A1 | 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS | EIF2AK4, GCN1, EIF5B | CCR4 1626/4885HSD11B1 828/4885SCN9A 2534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.